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1. Abstract 
Introduction 
Direct oral anticoagulants have become an attractive option for many patients requiring oral 
anticoagulation. For patients with non-valvular atrial fibrillation current guidelines propose their 
preferential use based on the results of large randomized trials. However, when applying those 
results to non-selected patients with multiple medical conditions in “real world” settings caution 
is prudent because the complication rate in these patients may be higher than in the study 
populations. The aims of this study were a) to assess the overall prevalence of anticoagulation 
in patients discharged in 2013 after being hospitalized for a variety of medical conditions and b) 
to analyse the selection of various oral anticoagulation regimens under “real world” conditions in 
the context of diverse comorbidities. 
Methods 
This study was designed as retrospective analysis of patients discharged from the medical inpa-
tient service at the University Hospital of Zurich in 2013. Patients receiving anticoagulation ther-
apy were identified by codes of the anatomical therapeutic chemical classification system of 
their discharge medications using a computerized search algorithm. Medications and patient 
characteristics were extracted from the electronic medical record. 
Results 
Between January 1 and December 31 1439 discharge reports were generated by the general 
internal medicine service, of which 304 (21.1%) were on patients receiving therapeutic antico-
agulation. Out of these, 228 patients received oral anticoagulants: 204 (89.5%) vitamin K an-
tagonists and 24 (10.5%) the direct oral anticoagulant rivaroxaban. Patients on rivaroxaban 
tended to have fewer diagnoses and discharge medications, better renal function and shorter 
hospital stays, but the differences to the patients on vitamin K antagonists were not statistically 
significant, possibly due to the relatively low number of patients receiving rivaroxaban.  
Conclusions 
In a “real world” setting 21.1% of general internal medicine patients were discharged on antico-
agulation therapy after hospitalization for a variety of conditions. The preferential use of vitamin 
K antagonists in 89.5% of orally anticoagulated patients likely reflects a combination of physi-
cians’ extensive experience and familiarity with vitamin K antagonists in addition to patient 
characteristics and clinical indications. The role of clinical patient characteristics on anticoagu-
lant choice remains to be clarified. 
 4 
2. Abbreviations 
 
AF   Atrial Fibrillation 
AHA/ACC/HRS American College of Cardiology / American Heart Association / Heart 
Rhythm Society 
ATC-code  Anatomical Therapeutic Chemical Classification System 
CKD-EPI  Chronic Kidney Disease Epidemiology Collaboration Equation 
DOACs  Direct Oral Anticoagulants 
DVT   Deep Vein Thrombosis  
eGFR   Estimated Glomerular Filtration Rate 
EHRA   European Heart Rhythm Association 
ESC   European Society of Cardiology 
GFR   Glomerular Filtration Rate  
ICU   Intensive Care Unit 
INR   International Normalized Ratio 
KISIM   Clinical Information System 
MWU   Mann-Whitney-U 
nvAF   Non-Valvular Atrial Fibrillation 
OAK   Oral Anticoagulation 
PE   Pulmonary Embolism 
Swissmedic  Swiss Agency for Therapeutic Products 
VKA   Vitamin K Antagonist 
VTE   Venous Thromboembolism 
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3. Introduction 
3.1. Background and Rationale 
Thromboembolic events due to atrial fibrillation (AF) and venous thromboembolism (VTE) are 
common and major contributors to morbidity and mortality worldwide. Currently, AF is estimated 
to affect 1.5-2% of the general population in the developed world (1). VTE, which includes deep 
vein thrombosis (DVT) and pulmonary embolism (PE), is the third most frequent cardiovascular 
disease with an annual incidence of 100-200/100’000 people (2). Death or chronic disability due 
to thromboembolic events can be reduced by anticoagulation therapy (1, 3). 
For many decades, vitamin K antagonists (VKAs) were the only oral anticoagulants (OAKs). 
VKA, as for example warfarin or phenprocoumon, are well-studied and have proven efficacy. 
VKA are appreciated because of the extensive experience gained over the last 50 years. None-
theless, there are several disadvantages, like the narrow therapeutic window, drug-drug or 
drug-food interactions, the wide range of individual dosing requirements and the necessity of 
monitoring the international normalized ratio (INR) (4). 
More recently, direct oral anticoagulants (DOACs) have become an attractive therapeutic option 
to treat and reduce the risk of thromboembolic events. In Switzerland, rivaroxaban was the first 
DOAC indicated for stroke and thromboembolism prevention licensed by the Swiss Agency for 
Therapeutic Products (Swissmedic) (5). Rivaroxaban was approved in 2008, followed by apixa-
ban in 2011, dabigatran in 2012 and most recently edoxaban in 2015.  
The indications for rivaroxaban (Xarelto®) (6), apixaban (Eliquis®) (7), dabigatran (Pradaxa®) (8) 
and edoxaban (Lixiana®) (9) are the reduction of the risk for stroke and thromboembolism in 
patients with non-valvular atrial fibrillation (nvAF) and the treatment and the prevention of DVT 
und PE. DOACs are not indicated for patients with mechanical heart valves. Rivaroxaban and 
apixaban are further indicated for the prevention of thromboembolism after hip or knee surgery.  
The effects of DOACs in patients with nvAF were investigated in several large-scale random-
ized phase III trials. The RE-LY study (10, 11) examined dabigatran, the ARISTOTLE study (12) 
apixaban and the ROCKET study (13) rivaroxaban. The efficacy of edoxaban was studied in the 
ENGAGE-AF study (14). In these studies, DOACs were compared with warfarin. The primary 
outcomes were stroke or systemic embolism. All of these four studies confirmed the non-
inferiority of DOACs compared to VKAs in patients with nvAF.  
DOAC treatment of patients with DVT was investigated in separate randomized trials. The direct 
thrombin inhibitor dabigatran was studied in the RE-COVER (15, 16) trial. The direct factor Xa 
inhibitors apixaban, rivaroxaban and edoxaban were studied separately in the AMPLIFY (apixa-
ban) (17), in the EINSTEIN (rivaroxaban) (18, 19) and in the Hokusai-VTE (edoxaban) (20) tri-
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als. These four studies were conducted in a non-inferiority design for DOACs versus warfarin. 
The efficacy outcome was recurrent VTE or fatal PE and the safety outcome was major bleed-
ing. In summary, these studies showed the non-inferiority of DOACs compared with warfarin in 
terms of DVT treatment and indicated a lower risk of major bleeding (21).  
The practical use of DOACs differs from VKAs in several aspects (22). In contrast to VKAs, 
DOACs are prescribed in a fixed dosing regimen without the need for therapeutic drug monitor-
ing. An initial heparin bridging is not necessary because of the rapid onset of action within ap-
proximately three hours. There is also no heparin bridging needed before planned surgical in-
tervention. However, a major problem is renal dysfunction. DOACs may accumulate in patients 
with low glomerular filtration rate (GFR). These patients have a higher risk of major bleeding, 
including haemorrhagic stroke as well as a higher risk of thromboembolic events (23, 24).  
Comorbid conditions are more common with increasing age. Nevertheless, DOACs showed 
even in elderly adults equal or greater efficacy than conventional anticoagulation therapy (25). 
The CHA2DS2-VASc-score and the HAS-BLED scores are based on various clinical characteris-
tics and comorbid conditions and can be helpful to identify patients who benefit from anticoagu-
lation therapy. However, there is ongoing discussion about the limited experience with DOACs 
in patients with complex and multiple medical disorders who may not have been included in the 
clinical trials on which the scoring systems are based. The aim of the present work was to ana-
lyse the anticoagulation regimens under “real world” conditions with the following study ques-
tions: 
1. How frequently were patients discharged from our internal medical service on (oral) anti-
coagulation? 
2. Which anticoagulation drugs were used? 
3. Is the choice of anticoagulant related to patient characteristics? 
3.2. Pharmacology of anticoagulants 
VKAs and DOACs impact on the coagulation cascade by different mechanisms of action (Figure 
1). VKA are coumarin derivatives and inhibit the synthesis of the vitamin K dependent coagula-
tion factors II (prothrombin), VII, IX and X in the liver. VKA displace vitamin K in specific enzyme 
systems and do not influence coagulation factors which have already been synthesized. Phen-
procoumon is a commonly used VKA in Switzerland. It takes 2-3 days before the action can be 
appreciated in the blood and requires frequent monitoring of the INR which should be between 
2 and 3 for most indications. The half-life of phenprocoumon is around 160 hours and the excre-
tion is in 35% renal (26).  
Rivaroxaban, apixaban, edoxaban and dabigatran bind reversibly to the catalytic pocket of free 
or clot-bound coagulation factors. Therefore, they have a shorter time to onset of action com-
pared to VKAs. Rivaroxaban is a factor Xa inhibitor. The bioavailability varies between 66% 
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when taken without food and almost 100% when taken with food. The time to onset of action is 
between 2 -4 h. The half-life is estimated between 5 -9 h in young and 11 – 13 h in elderly peo-
ple. A third of the drug is cleared renally (6).  
Apixaban is also a factor Xa inhibitor. Its bioavailability is about 50%. The clearance is in 27% 
renal. Therefore, the dosing of apixaban depends on the kidney function as well as patients’ age 
and weight. The time to onset of action varies between 3 - 4 h and the elimination half-life is 
about 12 h (7).  
The recently introduced factor Xa inhibitor edoxaban has a bioavailability of 62%. The ratio of 
non-renal to renal clearance is 50:50 and the onset of action is within 1 - 2 h with an elimination 
half-life of 10 – 14 h (9). 
In contrast to these factor Xa inhibiting DOACs, dabigatran is a prodrug that requires hepatic 
conversion to pharmacologically active acyl glucuronides which inhibit thrombin (coagulation 
factor IIa). Dabigatran’s onset of action is between 0.5 – 2 h with a half-life between 12 – 14 h 
and a mostly renal clearance (8).  
 
Figure 1: Points of action of oral anticoagulants in the coagulation cascade. (TF = tissue factor) 
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4. Methods 
4.1. Setting 
The University Hospital of Zurich is a Swiss teaching hospital providing highest level medical 
care in all specialties. Most of the patients admitted to the internal medicine service enter the 
hospital via the emergency unit with diverse medical conditions. Typically, many of these pa-
tients are elderly and/or suffer from several chronic conditions that require the coordinated care 
of various surgical and medical specialties. 
4.2. Study design 
This study was designed as a retrospective assessment of anticoagulant use in hospitalized 
patients of the internal medicine service at the University Hospital of Zurich. The study was 
based on a medical record review of the clinical information system (KISIM). The determinant of 
the study was defined as patients receiving anticoagulation therapy upon discharge between 
01.01.2013 – 31.12.2013.  
4.3. Sample 
All patients discharged on anticoagulation therapy from the internal medicine service of the Uni-
versity Hospital Zurich between 01.01.2013 – 31.12.2013 were identified per documentation of 
the anticoagulation drug in the discharge report. This information was collected using a comput-
erized search algorithm of the electronic medical records (KISIM, www.cistec.com) which cate-
gorized the anticoagulation according to the codes of the Anatomical Therapeutic Chemical 
Classification System (ATC-code). For better readability in the following text the word “discharge 
summary” is substituted by “patient”, although an exceptional patient may have been admitted 
to our hospital more than once in 2013. The following ATC-codes in the discharge medication 
defined the anticoagulation status: 
B  blood and blood forming organs 
B01  antithrombotic agents 
B01AA vitamin K antagonists 
B01AB heparin group  
B01AE direct thrombin inhibitors 
B01AF  direct factor Xa inhibitors 
B01AX other antithrombotic agents 
Patients with the explicit directive in the clinical information system that no clinical information 
may be used for research and patients under the age of 18 years were excluded.  
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4.4. Data collection 
In collaboration with the information technology unit of the University Hospital Zurich a search 
algorithm was designed to identify valid and not restricted hospital discharge summaries with 
the defined ATC-codes. The following patient data were extracted from the clinical information 
system onto a Microsoft Excel (Microsoft Excel, Version 15.18. Redmond, Washington: Mi-
crosoft Corp.) spreadsheet: patient number, case number, age, sex, length of hospital stay, dis-
charge drug list, type of anticoagulant therapy and total number of diagnosis items in the dis-
charge summary. Further information on renal function and OAK therapy prior to admission was 
collected by reviewing the medical records and laboratory tests of each patient. For quantifying 
and comparing the renal function, the serum concentration of creatinine as well as the estimat-
ed glomerular filtration rate (eGFR), using the chronic kidney disease epidemiology collabora-
tion equation (CKD-EPI) 2009, were analysed. 
4.5. Statistical Analyses 
Statistical analyses and data visualisations were done with SPSS (IBM SPSS Statistics for Win-
dows, Version 23.0. Armonk, NY: IBM Corp). Descriptive statistics with confidence intervals 
were used for assessing the proportion of anticoagulated patients out of all patients discharged 
from the internal medicine service in 2013. Secondary analyses addressed the choice of various 
anticoagulation regimens and its potential correlation with patient characteristics. Therefore, 
patient characteristics such as age, gender, kidney function and the length of hospital stay were 
studied, as well as the total number of drugs, total number of diagnoses and OAK therapy on 
admission. The data were tested for normal distribution by graphic interpretation in combination 
with the Shapiro-Wilk test. Chi-square test was used to compare categorical data. To test 
whether there were significant differences between continuous data the Mann-Whitney-U 
(MWU) test was used. Significant differences were based on a p-value < 0.05. 
4.6. Patient Privacy and Ethical Considerations 
The Excel spreadsheet contained exclusively anonymous patient information and the reported 
results preclude the identification of individual patients. According to requirements, the study 
was approved by the ethics committee Zurich (“Kantonale Ethikkommission Zürich”; 
www.kek.zh.ch, reference number KEK-ZH-Nr. 2014-0435). 
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5. Results 
5.1. Patient identification 
From January 01, 2013 through December 31, 2013 1439 discharge reports from the internal 
medicine service were identified, 305 of which contained anticoagulant medication(s). One pa-
tient aged under 18 years was excluded. 76 patients received parenteral anticoagulant drugs 
like heparin, dalteparin, enoxaparin, nadroparin or fondaparinux and were therefore not ana-
lysed as our study focused exclusively on OAK regimens. In total, 228 patients on OAK were 
included for further analysis (Figure 2). 
 
Figure 2: Study cohort. 
5.2. Primary outcome 
The main finding of this study is that out of 1439 discharge records in the year 2013, a total of 
304 (21.1%) documented either oral or parenteral anticoagulation therapy. Since the great ma-
jority of patients only had one hospitalisation during 2013, this result indicates that approximate-
ly 1/5 of patients discharged from our general internal medicine service received anticoagulation 
therapy: 75% of these (n=228, i.e. 15.8% of the total number of records) were discharged on 
OAK therapy with VKA or DOACs, whereas 25% (n=76, i.e. 5.3% of the total number of records) 
were discharged on various parenteral anticoagulation regimens. In 2013 204 (89.5%) of 228 
discharge records) documented VKA, almost exclusively phenprocoumon; one single patient 
was treated with acenocoumarol. Rivaroxaban was the only DOAC prescribed in 24 discharge 
reports, accounting for 10.5% of all orally anticoagulated patients and 1.7% of all discharged 
patients during 2013. 
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5.3. Gender 
Among the 204 patients with VKA in the discharge drug list, 114 (55.9%) were men. Out of the 
24 patients on rivaroxaban, 11 (45.8%) were men. The difference between men and women is 
not statistically significant (chi square test, P=0.39).  
5.4. Age 
In the rivaroxaban group the age ranged from 51 to 91 years. 2 (8.3%) patients were younger 
than 65 years, 6 (25.0%) between 65-75 years, 11 (45.8%) between 75-85 years and 5 (20.8%) 
were aged over 85 years. In the VKA group, the age distribution ranged from 25 years to 99 
years. The age group ≤65 years included 45 (22.0%) patients and the age group 65-75 years 
included 46 (22.5%) patients. In the next higher age group 75-85 years were 75 (36.8%) pa-
tients and 38 (18.6%) patients were aged ≥ 85 years. Regarding the mean of the rivaroxaban 
and the VKA group, there was no significant difference (MWU-test, P=0.33). The mean age in 
the rivaroxaban group was 76.1±10.6 years (median 79; interquartile range 76.0 - 84.0). The 
mean age of the VKA group was 73.2±13.9 years (median 76; interquartile range 65.25 - 82.0).  
 
Figure 3: Frequency distribution of anticoagulation according to age and treatment group. 
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5.5. Total number of drugs 
Patients on rivaroxaban therapy had a total of 8.9±4.3 drugs (median 7; interquartile range 6.0 - 
12.5) in their discharge report, patients on VKA therapy 10.3±4.7 different drugs (median 10; 
interquartile range 7.0 - 13.0) respectively. The total number of drugs did not significantly corre-
late with DOAC or VKA therapy (MWU-test, P=0.18). 
 
Figure 4: Frequency distribution of anticoagulation according to total number of drugs and 
treatment group. 
5.6. Total number of diagnoses 
Patients anticoagulated with rivaroxaban had a mean number of 8.1±2.7 diagnoses (median 
8.5; interquartile range 6.0-10.0). The number of diagnoses in the group of patients with VKA 
averages 8.3±3.1 (median 8, interquartile range 6.0-10.75) indicating that there is no significant 
difference (MWU-test, P=0.90). 
 
Figure 5: Frequency distribution of anticoagulation according to total number of diagnoses and 
treatment group. 
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5.7. Length of hospital stay 
On average, patients on rivaroxaban stayed 10.0±9.4 days (median 8.0; interquartile range 4.0–
13.0) in the hospital, whereas patients on VKA stayed 12.7±12.8 days (median 8.0; interquartile 
range 4.25–17.0), difference not significant (MWU-test, P=0.27). The histogram of the length of 
stay is considerably skewed contradicting a normal distribution. In both the rivaroxaban and the 
VKA group, there is a peak around 8 days and with a subsequent sharp decline. 
 
Figure 6: Frequency distribution of anticoagulation according to length of hospital stay and 
treatment group. 
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5.8. Renal function 
Patients receiving rivaroxaban at discharge (n=24 laboratory tests) had a mean eGFR of 
60.7±5.0 ml/min/1.73m2 (median 59; interquartile range 40.25-73.0) and a mean serum creati-
nine concentration of 103.0±9.6 µmol/l (median 86.5; interquartile range 68.5-125.75). In the 
VKA group the mean eGFR (n=192 laboratory tests) was 51.8±1.8 ml/min/1.73m2 (median 49.5; 
interquartile range 32.0-68.75) and the mean creatinine level (n=198 laboratory tests) was 
131.5±5.1 µmol/l (median 110; interquartile range 80.0 – 155.25). Patients discharged on VKA 
did not have a significantly lower renal function as judged by lower eGFR values (MWU-test, 
P=0.09) as well as no higher serum creatinine concentration (MWU-test, P=0.33).  
 
Figure 7: eGFR and creatinine levels according to treatment group. 
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Table 1: Characteristics of orally anticoagulated patients according to treatment group. (SD = 
standard deviation) 
 Rivaroxaban VKA P-value 
No. of patients  24 204  
Sex   P=0.39 
Male 11 114  
Female 13 90  
Age (years)    
Mean±SD 76.1±10.6 73.2±13.9 P=0.33 
Median 79 76  
Interquartile range 76.0-84.0 65.25 – 82.0  
< 65 yr (%) 2 (8.3) 45 (22.0)  
65 - < 75 yr (%) 6 (25.0) 46 (22.5)  
75 - < 85 yr (%) 11 (45.8) 75 (36.8)  
³ 85 yr (%) 5 (20.8) 38 (18.6)  
Total no. of drugs     
Mean±SD 8.9±4.3 10.3±4.7 P=0.18 
Median 7 10  
Interquartile range 6.0–12.5 7.0–13.0  
Total no. of diagnoses    
Mean±SD 8.1±2.7 8.3±3.1 P=0.90 
Median 8.5 8  
Interquartile range 6-10 6–10.75  
Length of hospital stay (days)    
Mean±SD 10.0±9.4 12.7±12.8 P=0.27 
Median 8 10  
Interquartile range 4.0–13.0 4.25–17.0  
eGFR (ml/min/1.73m2)    
 Mean±SD 60.7±5.0 51.8±1.8 P=0.09 
Median 59 49.5  
Interquartile range 40.25-73.0 32.0-68.75  
Creatinine (µmol/l)    
Mean±SD 103.0±9.6 131.5±5.1 P=0.33 
Median 86.5 110  
Interquartile range 68.5-125.75 80.0-155.25  
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6. Discussion 
6.1. Oral anticoagulation at hospital discharge in 2013 
In this retrospective study the frequency and choice of anticoagulants was analysed in patients 
discharged from an in-patient general medicine service after treatment of a variety of medical 
conditions, including, but not limited to thromboembolic complications and atrial fibrillation. In 
2013 89.5% of orally anticoagulated patients were discharged on a traditional VKA regimen and 
10.5% were discharged on rivaroxaban which at the time was the only DOAC on the hospital 
formulary. The use of OAK is influenced by changes of guidelines and recommendations for 
anticoagulation therapy. In 2011 DOACs were included in the update of the guidelines on the 
management of patients with AF of the American College of Cardiology / American Heart Asso-
ciation / Heart Rhythm Society (AHA/ACC/HRS) (27) without specific recommendations for the 
choice of anticoagulant. One year later, the ESC guideline for the management of AF stated, 
that DOACs “should be considered instead of adjusted-dose VKA for most patients with AF” (1). 
In April 2013 the EHRA published a practical guide on the use of new OAK in patients with 
nvAF (4). With increasing experience in the practical use of DOACs the AHA/ACC/HRS pub-
lished updated practice guidelines for the management of patients with nvAF in 2014 that rec-
ommended DOACs for patients unable to maintain a therapeutic INR on warfarin (28). The 2015 
guidelines of the ESC recommend for the first time the preferential use of DOACs instead of 
VKA for stroke prevention in patients with nvAF based on the reduced bleeding risk compared 
to warfarin in large randomized clinical trials (29).  
However, caution is needed when transferring results of the randomized trials into real world 
setting: clinical trial results are derived from defined study populations that may not be identical 
to unselected patients in general clinical practise. This is especially true when these drugs are 
used in elderly patients with multiple diagnoses and often borderline renal function. Further-
more, the large-scaled studies compared DOACs with warfarin, which is world-wide the most 
prescribed VKA (30). In Europe phenprocoumon and acenocoumarol are more commonly used 
which act in the same way as warfarin but with different pharmacokinetics. 
6.2. Comparison of the present results with the literature 
The prescription patterns of OAK have previously been studied on a large scale. Lauffenburger 
et. al. (31) and Desai et. al. (32) studied patients with nvAF initiating anticoagulation therapy, 
Lauffenburger et. al. between October 2010 and December 2012 and Desai et. al. between 
2010 and 2013. The results of Lauffenburger et. al. showed that out of 70498 patients initiating 
anticoagulation 30% got dabigatran and 8% rivaroxaban. Apixaban, FDA approved since De-
cember 2012, was not included in the study. The preferential use of dabigatran compared to 
rivaroxaban reflects the impact of the RELY-study which documented the efficacy and safety of 
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dabigatran. The study of Lauffenburger et. al. is consistent with our results that VKA is for many 
physicians still the drug of choice, as 62% of patients received warfarin. Desai et al. showed 
similar results. They reported that out of 45472 patients initiating an anticoagulation therapy 
57.7% received warfarin, 32.8% dabigatran, 9.3% rivaroxaban and 0.1% apixaban. 
Barnes et. al. (33) analysed the oral anticoagulation use in ambulatory visits for AF and venous 
thromboembolism in the United States. Out of around 2.5 million treatment visits in 2013, warfa-
rin was used in 75%, in 25% DOACs. Rivaroxaban was the most commonly prescribed DOAC 
with a rate of 57%, followed by dabigatran with 35% and apixaban with 7.5%. The higher pro-
portion of patients treated with DOACs compared to our results is most likely explained by the 
ambulatory setting of the study in contrast to our inpatient setting. Nevertheless, their results are 
in line with our findings that even in this study on non-hospitalized patients VKA were by far the 
most commonly prescribed OAK. 
6.3. Determinants of oral anticoagulant selection 
Before starting chronic oral anticoagulation therapy physicians have to evaluate three different 
possibilities: first, starting a therapy with VKA, second, starting with a DOAC and third, deciding 
against an OAK therapy due to contraindications and/or individual assessment of risk versus 
benefit. The choice between VKA and DOACs is likely to depend on patient factors like age, 
medications, co-morbid conditions, renal function and perceived bleeding risk. Therefore, we 
performed a pilot analysis of potentially relevant clinical features of patients on rivaroxaban ver-
sus phenprocoumon even though the small size of the rivaroxaban group is a limiting factor. 
Our data do not reveal significant differences between these two groups. However, patients 
receiving rivaroxaban tended to have less morbidity than patients on VKA: the number of diag-
noses and medications tended to be lower, the renal function tended to be better and the dura-
tion of hospitalization tended to be shorter. Taken together these results suggest that rivaroxa-
ban may have been prescribed in less severely ill patients. This hypothesis is consistent with 
the results of Desai et. al. (32) and Lauffenburger et. al. (31) despite the fact that they included 
only patients with nvAF and not with other clinical conditions like DVT and LE as in the present 
work. Desai et. al. showed that DOAC use was significantly associated with female sex, fewer 
concomitant medications and shorter hospital stays. Furthermore, patients with AF on anticoag-
ulation with DOACs tended to be younger and healthier. Lauffenburger et. al. found that patients 
with greater bleeding and ischemic stroke risk were more likely to be treated with warfarin, pos-
sibly because INR monitoring is felt to improve patient adherence. 
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6.4. Renal failure and the use of DOACs 
Since all DOACs are contraindicated in patients with renal failure, we tested the hypothesis that 
the selection of OAK was correlated with renal function. Rivaroxaban is contraindicated when 
the GFR is less than 15 ml/min (6). In our patients discharged on VKA the eGFR was between 
10 and 117 ml/min/1.73m2. Over 50% of them had an eGFR above 50 ml/min/1.73m2 so that 
DOACs could have been used at normal dosage. The present work failed to demonstrate statis-
tically significant differences of renal function between the patient groups. Nevertheless, the 
patients treated with rivaroxaban tended to have a better renal function suggesting that this im-
portant clinical characteristic may have an influence on anticoagulant choice (see above). 
6.5. Limitations 
The present retrospective analysis has several limitations. Patient selection was based on anti-
coagulation treatment at discharge and not on the indications of anticoagulation therapy. Hence, 
we did not exclude patients with valvular AF, mechanical heart valves, DVT or LE. Moreover, 
the number of patients without anticoagulation despite an indication is not known. Patients of 
the intensive care units (ICU) were only included if they had been transferred to the regular 
medical service prior to discharge. Due to the computerized search algorithm any patients 
transferred directly from the ICUs to outside institutions or patients dying in the intensive care 
units were not identified.  
6.6. Future studies 
It takes time until the results of the large scale clinical trials on defined populations are trans-
ferred into real world clinical practice. During the observation period of this study the restrictive 
use of these new drugs in elderly patients with multiple diagnoses seemed prudent. However, 
with increasing familiarity of physicians DOACs are likely to overtake VKA as the anticoagulants 
of choice for the most common indications non-valvular atrial fibrillation and venous thrombo-
embolism, but VKA can be expected to retain an important role for individual patients with se-
lected indications.  
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6.7. Conclusions 
Our results show that 304 (21.1%) of 1439 of patients discharged in 2013 from our general 
medical service after hospitalization for a variety of conditions received anticoagulation. The 
only DOAC prescribed upon discharge was rivaroxaban in 10.5% of orally anticoagulated pa-
tients. Patients discharged on rivaroxaban were not statistically different from patients on VKA 
despite a trend suggesting a higher morbidity of patients on VKA. This hypothesis could be 
tested in future studies. Our main result, i.e. that in 2013 21.1% of general medicine patients 
were discharged from hospital on anticoagulation is consistent with current guidelines. The 
preferential use of VKA in 89.5% of orally anticoagulated patients likely reflects a combination of 
patient characteristics and clinical indications because in contrast to VKA DOACs are not ap-
proved for all indications. However, physician behaviour also needs to be taken into account as 
physicians are cautious when it comes to changing prescribing patterns. Therefore, observa-
tional studies in real world settings are an important adjunct to randomized clinical trials for the 
implementation of evidence-based guidelines into clinical practice.  
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